The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Therapeutic Antibodies and Proteins Market Research Report 2024
Synopsis
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
The global Recombinant Therapeutic Antibodies and Proteins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
This report aims to provide a comprehensive presentation of the global market for Recombinant Therapeutic Antibodies and Proteins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Therapeutic Antibodies and Proteins.
Report Scope
The Recombinant Therapeutic Antibodies and Proteins market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Therapeutic Antibodies and Proteins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Therapeutic Antibodies and Proteins companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Segment by Type
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Segment by Application
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Therapeutic Antibodies and Proteins companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
The global Recombinant Therapeutic Antibodies and Proteins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
This report aims to provide a comprehensive presentation of the global market for Recombinant Therapeutic Antibodies and Proteins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Therapeutic Antibodies and Proteins.
Report Scope
The Recombinant Therapeutic Antibodies and Proteins market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Therapeutic Antibodies and Proteins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Therapeutic Antibodies and Proteins companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Segment by Type
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Segment by Application
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Therapeutic Antibodies and Proteins companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Plasma Protein
1.2.3 Fusion Proteins
1.2.4 Monoclonal Antibodies
1.2.5 Hormones
1.2.6 Enzyme
1.2.7 Coagulation Factors
1.2.8 Others
1.3 Market by Application
1.3.1 Global Recombinant Therapeutic Antibodies and Proteins Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Hematology
1.3.4 Immunology
1.3.5 Endocrinology
1.3.6 Infectious Disease
1.3.7 Cardiovascular Disease
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Perspective (2019-2030)
2.2 Recombinant Therapeutic Antibodies and Proteins Growth Trends by Region
2.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Region (2019-2024)
2.2.3 Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Region (2025-2030)
2.3 Recombinant Therapeutic Antibodies and Proteins Market Dynamics
2.3.1 Recombinant Therapeutic Antibodies and Proteins Industry Trends
2.3.2 Recombinant Therapeutic Antibodies and Proteins Market Drivers
2.3.3 Recombinant Therapeutic Antibodies and Proteins Market Challenges
2.3.4 Recombinant Therapeutic Antibodies and Proteins Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue
3.1.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue (2019-2024)
3.1.2 Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Players (2019-2024)
3.2 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Therapeutic Antibodies and Proteins Revenue
3.4 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio
3.4.1 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Therapeutic Antibodies and Proteins Revenue in 2023
3.5 Recombinant Therapeutic Antibodies and Proteins Key Players Head office and Area Served
3.6 Key Players Recombinant Therapeutic Antibodies and Proteins Product Solution and Service
3.7 Date of Enter into Recombinant Therapeutic Antibodies and Proteins Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Type
4.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Type (2019-2024)
4.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2025-2030)
5 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Application
5.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Application (2019-2024)
5.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size (2019-2030)
6.2 North America Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2019-2024)
6.4 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2019-2030)
7.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2019-2024)
7.4 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size (2019-2030)
8.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2019-2024)
8.4 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size (2019-2030)
9.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2019-2024)
9.4 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size (2019-2030)
10.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2019-2024)
10.4 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Recombinant Therapeutic Antibodies and Proteins Introduction
11.1.4 Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.1.5 Abbott Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Recombinant Therapeutic Antibodies and Proteins Introduction
11.2.4 Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Biogen
11.3.1 Biogen Company Detail
11.3.2 Biogen Business Overview
11.3.3 Biogen Recombinant Therapeutic Antibodies and Proteins Introduction
11.3.4 Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.3.5 Biogen Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Introduction
11.4.4 Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.4.5 Eli Lilly Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Recombinant Therapeutic Antibodies and Proteins Introduction
11.5.4 Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Johnson and Johnson
11.6.1 Johnson and Johnson Company Detail
11.6.2 Johnson and Johnson Business Overview
11.6.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Introduction
11.6.4 Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.6.5 Johnson and Johnson Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Introduction
11.7.4 Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Novo Nordisk
11.8.1 Novo Nordisk Company Detail
11.8.2 Novo Nordisk Business Overview
11.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Introduction
11.8.4 Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.8.5 Novo Nordisk Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Introduction
11.9.4 Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Introduction
11.10.4 Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2019-2024)
11.10.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
